Saturday 17 October 2026 Export OPK’s income statement to Excel — free account

OPKO Health, Inc.

OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.53 0.08 −4.97%

Follow OPK

Alert me

Market cap: $1.2B
P/E: 0.0×
Fwd P/E: −4.7×
Dividend yield: —
F-score: 4/9
Altman Z: −0.42
Beneish M: −2.81
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.99

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 49.20%

Capital & Financial Ratios $m

Market Cap 1,200.00

Revenue 587.90

Net Income (72.89)

Free Cash Flow (133.73)

Net Debt 46.51

Current Ratio 3.35

Debt/Equity 0.29

P/E ratio 0.00

Fwd P/E (4.71)

P/S ratio 1.97

P/B ratio 0.98

Past 5Y EPS Growth —

This Y EPS Growth 24.44%

Next Y EPS Growth (18.38%)

Next Y revenue growth (6.09%)

Next 5Y EPS Growth 6.53%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 66.16%

10-year low 10-year high

P/B against its own 10 years 50.24%

10-year low 10-year high

EV/Sales against its own 10 years 65.79%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	96	432	369	301
Receivables	123	118	90	82
Inventory	66	57	66	62
Other	—	—	—	—
	309	662	582	500

	2023	2024	2025	Q'26
Payables	70	47	41	50
ST’ Debt	27	15	10	11
Other	—	—	—	—
	200	193	147	149

Compound Annual Growth %

	10y	5y	3y
Sales	2.13%	(15.82%)	(15.45%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(4.36%)	(5.38%)	(6.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	124	164	—	—	—
’25	150	157	152	148	607
’24	174	182	174	184	713
’23	238	265	179	182	863
’22	329	310	180	185	1,004
’21	545	442	386	401	1,775
’20	211	301	428	495	1,435

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(43)	—	—	—
’25	(35)	(83)	(35)	(26)	(179)
’24	(36)	(26)	(77)	(44)	(183)
’23	(23)	0	33	(38)	(28)
’22	(20)	(11)	(32)	(32)	(95)
’21	26	(15)	33	(6)	38
’20	(43)	(14)	63	34	39

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(46)	—	—	—
’25	(38)	(87)	(38)	(28)	(191)
’24	(40)	(34)	(85)	(50)	(208)
’23	(25)	(6)	29	(40)	(42)
’22	(25)	(16)	(39)	(38)	(118)
’21	17	(24)	92	(12)	72
’20	(49)	(26)	53	28	6

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	(0.01)	—	—	—
’25	(0.10)	(0.19)	0.03	(0.04)	(0.30)
’24	(0.12)	(0.01)	0.03	0.01	(0.08)
’23	(0.02)	(0.03)	(0.11)	(0.09)	(0.25)
’22	(0.08)	(0.14)	(0.11)	(0.11)	(0.46)
’21	0.05	(0.03)	0.04	(0.11)	(0.05)
’20	(0.09)	0.05	0.04	0.05	0.05

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.12	4.50	2.34	1.33	1.12	3.26	1.03	1.00	0.85	1.11	Analyst estimates 2026–2028 Powerpack
	High	12.15	9.55	6.40	3.94	6.47	6.27	4.96	2.24	1.76	2.04
People
People	Employees	6,041	6,030	5,690	6,096	5,269	5,767	4,196	3,930	2,997	1,373
	Revenue/emp, $m	0.18	0.16	0.17	0.15	0.27	0.31	0.24	0.22	0.24	0.44
Income, $m
Income, $m	Revenue	1,117	966	990	902	1,435	1,775	1,004	863	713	607
	Gross margin, %	45.28	35.80	38.94	36.53	37.69	32.77	28.70	36.84	30.64	33.93
	EBT	(97)	(272)	(177)	(305)	49	(14)	(392)	(184)	(10)	(241)
	EBT margin, %	(8.66)	(28.15)	(17.90)	(33.81)	3.39	(0.79)	(38.99)	(21.35)	(1.45)	(39.77)
	Net income	(48)	(305)	(153)	(315)	31	(30)	(328)	(189)	(53)	(226)
	Depreciation	97	102	98	95	86	80	110	107	100	97
Per share, $
Per share, $	Revenue	2.03	1.73	1.76	1.51	2.24	2.74	1.40	1.15	1.03	0.81
	Earnings	(0.09)	(0.55)	(0.27)	(0.53)	0.05	(0.05)	(0.46)	(0.25)	(0.08)	(0.30)
	Cash flow	0.06	(0.16)	(0.19)	(0.29)	0.06	0.06	(0.13)	(0.04)	(0.26)	(0.24)
	Capex	(0.04)	(0.07)	(0.05)	(0.02)	(0.05)	0.05	(0.03)	(0.02)	(0.04)	(0.02)
	Free cash flow	0.02	(0.23)	(0.24)	(0.31)	0.01	0.11	(0.16)	(0.06)	(0.30)	(0.25)
	Book value	3.80	3.30	3.18	2.71	2.61	2.60	2.17	1.85	1.97	1.69
	Shares, m	551	559	563	595	641	648	719	752	694	751
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	79.00	0.00	0.00	0.00	0.00	0.00
	P/S	4.48	2.88	1.71	0.97	1.76	1.76	0.87	1.37	1.43	1.56
	P/B	2.39	1.51	0.95	0.54	1.51	1.85	0.56	0.85	0.75	0.75
	EV/Sales	4.38	2.82	1.71	1.12	1.89	1.79	0.97	1.54	1.43	1.51
	EV/FCF	998.81	(19.31)	(11.62)	(5.19)	(685.78)	51.20	(7.60)	(25.62)	(4.68)	(4.58)
Cash, $m
Cash, $m	Operating cash flow	32	(92)	(109)	(173)	39	38	(95)	(28)	(183)	(179)
	Capex	(22)	(39)	(27)	(12)	(33)	34	(23)	(14)	(25)	(12)
	Free cash flow	10	(131)	(136)	(185)	6	72	(118)	(42)	(208)	(191)
Balance, $m
Balance, $m	Working capital	220	37	29	75	148	493	181	109	469	435
	Total debt	56	41	95	221	258	203	247	242	434	342
	Net debt	(113)	(50)	(2)	135	186	68	94	146	2	(27)
	Shareholders’ equity	2,092	1,844	1,791	1,615	1,672	1,685	1,562	1,389	1,365	1,268
Returns, %
Returns, %	ROA	(1.74)	(11.40)	(6.07)	(13.23)	1.28	(1.24)	(14.38)	(9.04)	(2.53)	(10.92)
	ROIC	(3.05)	(9.64)	(5.98)	(9.79)	1.94	0.67	(8.54)	(6.39)	(6.95)	(5.91)
	ROE	(2.38)	(15.51)	(8.42)	(18.49)	1.86	(1.80)	(20.23)	(12.80)	(3.86)	(17.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VCYT Veracyte, Inc.	$3.6B	29.9×	45.1×	+15.49% (above 0%: growing)	n/m	+32.95% (above 0%: growing)	72.21%	15.29%	Compare
CDNA CareDx, Inc.	$3.5B	29.7×	2,967×	+52.23% (above 0%: growing)	n/m	+223.42% (above 0%: growing)	73.50%	85.81%	Compare
NEO NeoGenomics, Inc.	$2.2B	— (loss-making)	— (loss-making)	+11.21% (above 0%: growing)	n/m	−16.18% (below 0%: shrinking)	45.56%	(4.85%)	Compare
WGS GeneDx Holdings Corp.	$2.1B	— (loss-making)	— (loss-making)	+11.44% (above 0%: growing)	n/m	−585.59% (below 0%: shrinking)	68.37%	(15.25%)	Compare
PSNL Personalis, Inc.	$1.7B	— (loss-making)	— (loss-making)	+29.96% (above 0%: growing)	n/m	−123.46% (below 0%: shrinking)	21.21%	(150.25%)	Compare
OPK OPKO Health, Inc.	$1.2B	— (loss-making)	— (loss-making)	+4.32% (above 0%: growing)	n/m	+46.46% (above 0%: growing)	48.92%	(4.26%)
CSTL Castle Biosciences, Inc.	$1.0B	— (loss-making)	— (loss-making)	+20.14% (above 0%: growing)	n/m	−43.33% (below 0%: shrinking)	77.11%	(2.96%)	Compare
FLGT Fulgent Genetics, Inc.	$587.2M	— (loss-making)	— (loss-making)	+4.38% (above 0%: growing)	n/m	+25.36% (above 0%: growing)	30.07%	(42.25%)	Compare
MYGN Myriad Genetics, Inc.	$416.1M	— (loss-making)	— (loss-making)	−10.51% (below 0%: shrinking)	n/m	+43.90% (above 0%: growing)	66.60%	(20.40%)	Compare
Median of peers	$1.9B	—	—	+13.47%	—	+4.59%	67.49%	(10.05%)

All 52 Diagnostics & Research stocks →

OPKO Health, Inc. (OPK) key facts

Concern: OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024.
OPKO Health, Inc. (OPK) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OPK traded at $1.53, a market capitalization of $1.2 billion.
Return on equity was −17.1% and debt-to-equity 0.29.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.